You are here
- Home
- Drug Products
All Drug Products
- Expand All
- Collapse All
-
expand
A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed After 2nd Line Chemotherapy.
- Study Id
- D7913L00138
- Disease
- lung cancer
- Drug Name
- IRESSA
- Study Name
- Icarus
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A randomized, open-label, multiple-center, parallel group study to compare the platelet inhibition with VerifyNow assay of ticagrelor versus clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)
- Study Id
- D5130L00014
- Disease
- acute coronary syndrome
- Drug Name
- Brilinta
- Study Name
- D5130L00014
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections
- Study Id
- D3720C00001
- Disease
- infectious diseases, skin and soft tissue infection
- Study Name
- D3720C00001
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
- Study Id
- D2850C00001
- Disease
- Cancer and Infection Research Area
- Study Name
- D2850C00001
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry
- Study Id
- NIS-CDE-XXX-2011/1
- Disease
- acute coronary syndrome
- Drug Name
- non drug study (cardiovascular)
- Study Name
- NIS-CDE-XXX-2011/1
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase I Open-Label Study to Assess the Safety and Tolerability of AZD2281(KU-0059436) in Combination with carboplatin (phase I), or in combination with a carboplatin/paclitaxel doublet (phase IIa), or in combination with paclitaxel (phase IIb) in the Treatment of Patients with Advanced Solid Tumours.
- Study Id
- D0810C00004
- Disease
- solid tumour
- Drug Name
- Olaparib
- Study Name
- KU36-96
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
- Study Id
- D1532C00067
- Disease
- non-small cell lung cancer
- Drug Name
- AstraZeneca Oncology and Infection Development Drugs
- Study Name
- D1532C00067
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Study to derive normative distribution of CIMT and to determine its cOrrelation with cardiovascular Risk factors in asymptomatic nationwidE Indian population. (SCORE India)
- Study Id
- NIS-CIN-XXX-2011/2
- Disease
- cardiovascular diseases
- Study Name
- NIS-CIN-XXX-2011/2
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Disease
- lymphoma
- Drug Name
- AstraZeneca Oncology and Infection Development Drugs
- Study Name
- D4302C00001
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers
- Study Id
- D4280C00009
- Disease
- drug safety, pharmacokinetics
- Drug Name
- CAZ-104
- Study Name
- D4280C00009
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
- Expand All
- Collapse All
